Sun Pharma Receives FDA Approval for Next Generation BLU-U® Blue Light Photodynamic Therapy Illuminator for Actinic Keratosis

Sun Pharmaceutical Industries Limited (Sun Pharma) has announced that the U.S. Food and Drug Administration (FDA) has granted premarket approval application (PMA) approval of the next generation of BLU-U® Blue Light Photodynamic Therapy (PDT) Illuminator. The new LED BLU-U model features light emitting diode light (LED) panels as a replacement for the previous model’s fluorescent tubes. The new model is indicated for the treatment of minimally to moderately thick actinic keratoses (AK) of the face, scalp, or upper extremities. The LED BLU-U is approved for the same indications as the previous model but takes up less space in a dermatologist’s office, and has a more flexible five-panel shape, improved LED arrangement, lighter weight, and other updated functions that may increase patient comfort and ease of use.